Jul 31, 2013 7:00 am EDT NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013
Jul 25, 2013 7:00 am EDT NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular Testing
Apr 25, 2013 7:00 am EDT NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter
Feb 14, 2013 7:00 am EST NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012
Feb 5, 2013 2:25 pm EST NeoGenomics Schedules its Q4 and Full Year 2012 Earnings Release for February 14, 2013
Dec 17, 2012 7:00 am EST NeoGenomics Validates and Launches NeoSITE™ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer
